These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 12811682)

  • 1. Cinacalcet hydrochloride (Amgen).
    Iqbal J; Zaidi M; Schneider AE
    IDrugs; 2003 Jun; 6(6):587-92. PubMed ID: 12811682
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cinacalcet: AMG 073, Calcimimetics--Amgen/NPS Pharmaceuticals, KRN 1493, NPS 1493.
    Drugs R D; 2003; 4(6):349-51. PubMed ID: 14584963
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cinacalcet: Amg 073, calcimimetics--Amgen/NPS Pharmaceuticals.
    Drugs R D; 2003; 4(1):39-41. PubMed ID: 12568635
    [No Abstract]   [Full Text] [Related]  

  • 4. Cinacalcet HCl: a novel treatment for secondary hyperparathyroidism caused by chronic kidney disease.
    Torres PU
    J Ren Nutr; 2006 Jul; 16(3):253-8. PubMed ID: 16825031
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cinacalcet: An oral calcimimetic agent for the management of hyperparathyroidism.
    Dong BJ
    Clin Ther; 2005 Nov; 27(11):1725-51. PubMed ID: 16368445
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cinacalcet treatment in dialysis patients with secondary hyperparathyroidism: effects and open issues.
    Drüeke TB
    Ther Apher Dial; 2008 Oct; 12 Suppl 1():S2-12. PubMed ID: 19032522
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of secondary hyperparathyroidism in CKD patients with cinacalcet and/or vitamin D derivatives.
    Drüeke TB; Ritz E
    Clin J Am Soc Nephrol; 2009 Jan; 4(1):234-41. PubMed ID: 19056615
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New strategies for the treatment of hyperparathyroidism incorporating calcimimetics.
    de Francisco AL
    Expert Opin Pharmacother; 2008 Apr; 9(5):795-811. PubMed ID: 18345956
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis.
    Block GA; Martin KJ; de Francisco AL; Turner SA; Avram MM; Suranyi MG; Hercz G; Cunningham J; Abu-Alfa AK; Messa P; Coyne DW; Locatelli F; Cohen RM; Evenepoel P; Moe SM; Fournier A; Braun J; McCary LC; Zani VJ; Olson KA; Drüeke TB; Goodman WG
    N Engl J Med; 2004 Apr; 350(15):1516-25. PubMed ID: 15071126
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Implementation of 'K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease' after the introduction of cinacalcet in a population of patients on chronic haemodialysis.
    Arenas MD; Alvarez-Ude F; Gil MT; Moledous A; Malek T; Nuñez C; Devesa R; Carretón MA; Soriano A
    Nephrol Dial Transplant; 2007 Jun; 22(6):1639-44. PubMed ID: 17277339
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Economic analysis of cinacalcet in combination with low-dose vitamin D versus flexible-dose vitamin D in treating secondary hyperparathyroidism in hemodialysis patients.
    Shireman TI; Almehmi A; Wetmore JB; Lu J; Pregenzer M; Quarles LD
    Am J Kidney Dis; 2010 Dec; 56(6):1108-16. PubMed ID: 20951487
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecule of the month. Cinacalcet hydrochloride.
    Drug News Perspect; 2003 Sep; 16(7):470. PubMed ID: 14668942
    [No Abstract]   [Full Text] [Related]  

  • 13. Normalization of lithium-induced hypercalcemia and hyperparathyroidism with cinacalcet hydrochloride.
    Sloand JA; Shelly MA
    Am J Kidney Dis; 2006 Nov; 48(5):832-7. PubMed ID: 17060004
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Calcium, calcimimetics and clinical outcomes.
    Block G
    Clin J Am Soc Nephrol; 2006 Mar; 1(2):170-1. PubMed ID: 17699205
    [No Abstract]   [Full Text] [Related]  

  • 15. Cinacalcet in hyperfunctioning parathyroid diseases.
    Imanishi Y; Inaba M; Kawata T; Nishizawa Y
    Ther Apher Dial; 2009 Oct; 13 Suppl 1():S7-S11. PubMed ID: 19765257
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Parathyroidectomy versus cinacalcet hydrochloride-based medical therapy in the management of hyperparathyroidism in ESRD: a cost utility analysis.
    Narayan R; Perkins RM; Berbano EP; Yuan CM; Neff RT; Sawyers ES; Yeo FE; Vidal-Trecan GM; Abbott KC
    Am J Kidney Dis; 2007 Jun; 49(6):801-13. PubMed ID: 17533023
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cinacalcet: new drug. Secondary hyperparathyroidism: where are the clinical data?
    Prescrire Int; 2006 Jun; 15(83):90-3. PubMed ID: 16764095
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cinacalcet hydrochloride therapy for secondary hyperparathyroidism in hemodialysis patients.
    El-Shafey EM; Alsahow AE; Alsaran K; Sabry AA; Atia M
    Ther Apher Dial; 2011 Dec; 15(6):547-55. PubMed ID: 22107691
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug Insight: renal indications of calcimimetics.
    Shahapuni I; Monge M; Oprisiu R; Mazouz H; Westeel PF; Morinière P; Massy Z; Choukroun G; Fournier A
    Nat Clin Pract Nephrol; 2006 Jun; 2(6):316-25. PubMed ID: 16932453
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Persistent and symptomatic post-transplant hyperparathyroidism: a dramatic response to cinacalcet.
    Leonard N; Brown JH
    Nephrol Dial Transplant; 2006 Jun; 21(6):1736. PubMed ID: 16364985
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.